Company Description
BriaCell Therapeutics Corp., a pre-clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care.
Its lead candidate is Bria-IMT, a targeted immunotherapy program against end-stage breast cancer that is in Phase 3 clinical trials.
The company develops Bria-OTS, a personalized off-the-shelf immunotherapy; and a soluble CD80 protein therapeutic that acts as a stimulator of the immune system and an immune checkpoint inhibitor.
It has a license agreement with the University of Maryland, Baltimore County to develop and commercialize soluble CD80 as a biologic agent for the treatment of cancer.
BriaCell Therapeutics Corp., has a collaboration with MSK Accelerator to accelerate the clinical development of Bria-OTS+ for multiple cancer indications including metastatic breast cancer, prostate cancer, and other cancers.
The company is headquartered in West Vancouver, Canada.
| Country | Canada |
| Founded | 2014 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 16 |
| CEO | William Williams |
Contact Details
Address: Bellevue Centre, Suite 300 West Vancouver, BC V7T 2X1 Canada | |
| Phone | 604 921 1810 |
| Website | briacell.com |
Stock Details
| Ticker Symbol | BCTX |
| Exchange | NASDAQ |
| Fiscal Year | August - July |
| Reporting Currency | USD |
| CIK Code | 0001610820 |
| CUSIP Number | 107930307 |
| ISIN Number | CA1079303071 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. William V. Williams FCPA, M.D. | Chief Executive Officer, President and Director |
| Gadi Levin B.Com., C.A., CPA, M.B.A. | Chief Financial Officer and Corporate Secretary |
| Dr. Miguel A. Lopez-Lago Ph.D. | Chief Scientific Officer |
| Dr. Giuseppe Del Priore M.D., M.P.H. | Chief Medical Officer |
| Dr. Charles Louis Wiseman FACP, M.D. | Founder, Principal Research Advisor and Member of Scientific Advisory Board |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Feb 26, 2026 | 25-NSE | Filing |
| Feb 20, 2026 | 8-K | Current Report |
| Feb 12, 2026 | DEF 14A | Other definitive proxy statements |
| Jan 23, 2026 | SCHEDULE 13G | Filing |
| Jan 15, 2026 | 8-K | Current Report |
| Jan 14, 2026 | 424B4 | Prospectus |
| Jan 13, 2026 | EFFECT | Notice of Effectiveness |
| Jan 13, 2026 | S-1MEF | Registration adding securities to prior Form S-1 registration |
| Jan 13, 2026 | CERT | Certification by an exchange approving securities for listing |
| Jan 13, 2026 | 8-A12B | Registration of securities |